Skip to main
ALLR
ALLR logo

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc is positioned favorably in the oncology market with its clinical-stage development of stenoparib, an innovative therapy demonstrating median overall survival exceeding 25 months for patients with advanced recurrent ovarian cancer. The company's valuation appears attractive, supported by positive net present value (NPV) analyses indicating significant upside potential from the current share price. Furthermore, the proprietary Drug Response Predictor (DRP) technology enables refined patient selection, which may enhance clinical outcomes and further solidify the company's market position in the highly competitive pharmaceutical landscape.

Bears say

Allarity Therapeutics Inc. reported a net loss of $2.8 million, with an earnings per share (EPS) of $(0.19), which was slightly better than the estimated EPS of $(0.23), yet still indicates ongoing financial challenges. The company's financial health is further compromised by significant risks, including liquidity issues, potential failures in clinical trials, and the ability to secure necessary regulatory approvals for its lead candidate, stenoparib. Additionally, macroeconomic factors and changing investor sentiment towards biotech stocks add to the uncertainties, leading to a cautious outlook on the company's future performance.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.